United TherapeuticsBSP:U2TH34 65 EV-to-FCF is 19.51 as of Jul. 07, 2026, which is 72% above its 10-year median of 11.33. GuruFocus rates BSP:U2TH34 with a GF Score™ of 65/100 and a GF Value™ of R$97.21 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 564 Drug Manufacturers companies, United Therapeutics ranks better than 52.3% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, United Therapeutics's Enterprise Value is R$105,647 Mil.
United Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was R$5,416 Mil. Therefore, United Therapeutics's EV-to-FCF for today is 19.51.
The historical rank and industry rank for United Therapeutics's EV-to-FCF or its related term are showing as below:
BSP:U2TH34'
s EV-to-FCF Range Over the Past 10 Years
Min: -15.99 Med: 11.33 Max: 25.33
Current: 19.88
During the past 13 years, the highest EV-to-FCF of United Therapeutics was 25.33. The lowest was -15.99. And the median was 11.33.
BSP:U2TH34's EV-to-FCF is ranked better than 52.3% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.75
vs BSP:U2TH34: 19.88
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
United Therapeutics (BSP:U2TH34) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
United Therapeutics's PE Ratio (TTM) for today is calculated as:
United Therapeutics's share price for today is R$137.50.
United Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$7.319.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
United Therapeutics EV-to-FCF Related Terms
United Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for United Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:U2TH34 vs VTRS, NBIX, ZTS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where United Therapeutics's EV-to-FCF falls into.
United Therapeutics's current Enterprise Value is R$105,647 Mil.
United Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$5,416 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (BSP:U2TH34) has a EV-to-FCF of 19.51 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on United Therapeutics and its competitors. This is 72% above median its historical median of 11.33. According to the industry distribution chart, United Therapeutics ranks #269 out of 564 companies in the Drug Manufacturers industry, placing it in the top 47.7%.
Is United Therapeutics' EV-to-FCF too high?
United Therapeutics' current EV-to-FCF of 19.51 is 72% above median its 10-year median of 11.33. The Drug Manufacturers industry median EV-to-FCF is 20.75. United Therapeutics' value of 19.51 is 6% below this industry median. Based on the distribution chart, United Therapeutics ranks #269 out of 564 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, United Therapeutics has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' EV-to-FCF compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #269 out of 564 companies for EV-to-FCF. This puts United Therapeutics in the upper half of its industry. The industry median EV-to-FCF is 20.75. United Therapeutics' value of 19.51 is 6% below this benchmark. While the company's 10-year median is 11.33 vs. the industry median of 20.75, United Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.75, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current EV-to-FCF of 19.51 is 6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current EV-to-FCF is 19.51, which is 72% above median its own 10-year median of 11.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (BSP:U2TH34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$97.21, compared to a current price of R$137.50 — trading 41.4% above its estimated fair value. The current EV-to-FCF is 19.51, which is 72% above median its 10-year median of 11.33 and 6% below the Drug Manufacturers industry median of 20.75. United Therapeutics' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For United Therapeutics (BSP:U2TH34), the current EV-to-FCF is 19.51 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (BSP:U2TH34) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of R$137.50 is trading 41.4% above its estimated GF Value™ of R$97.21.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for BSP:U2TH34:
EV-to-FCF: 19.51 (72% above median its 10-year median of 11.33)
GF Value™: R$97.21 vs. price of R$137.50 (41.4% above fair value)
Industry Position: 6% below the Drug Manufacturers median (#269 of 564)
No single metric tells the full story. See the BSP:U2TH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
65GF Score
Get the complete analysis for BSP:U2TH34
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:U2TH34 has been successfully added to your 
